All News
Filter News
Found 808,679 articles
-
BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
3/23/2023
BioStem Technologies is commending the U.S. Department of Health and Human Services Office of Inspector General's (HHS OIG) recent recommendation for the Centers for Medicare and Medicaid Services (CMS) to quickly address issues associated with Average Sales Price (ASP) reporting requirements for skin substitute products.
-
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
3/23/2023
Cognition Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
-
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
3/23/2023
Monte Rosa Therapeutics, Inc. today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors.
-
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
3/23/2023
Dyne Therapeutics, Inc. today announced that DYNE-251 was granted U.S. Food and Drug Administration (FDA) orphan drug and rare pediatric disease designations.
-
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies
3/23/2023
Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.
-
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
3/23/2023
Enveric Biosciences, Inc. today announced that it has entered into an agreement with Avance Clinical for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeting the treatment of anxiety disorders.
-
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
3/23/2023
Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/23/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Cambrium Launches NovaColl™: First Micro-Molecular & Skin-Identical Collagen Ingredient for Personal Care Industry
3/23/2023
Biotechnology company Cambrium has launched its first product: NovaColl™. It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.
-
Fruit Logistica 2023: Bayer Focuses on Partnerships, Sustainability, and Innovation
3/23/2023
At this year's Fruit Logistica taking place in Berlin from February 8-10 Bayer highlights its solutions towards regenerative agriculture, meaning the balance between productivity outcomes and environmental protection, while supporting the needs of society and farmers.
-
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
3/23/2023
Today, Arch Biopartners Inc. announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program.
-
TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
3/23/2023
TELA Bio, Inc today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's OviTex PRS Long-Term Resorbable product.
-
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
3/23/2023
Graf Acquisition Corp. IV and NKGen Biotech, Inc. announced that they have signed a non-binding letter of intent to pursue a business combination.
-
Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs
3/23/2023
Curia, a leading contract research, development and manufacturing organization, announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally.
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
3/23/2023
Monopar Therapeutics Inc. today announced fourth quarter and full-year 2022 financial results and summarized recent developments.
-
Volpara to showcase comprehensive product offerings at NCoBC 2023
3/23/2023
Volpara Health Technologies Ltd., a global leader in software for the early detection of cancer, is attending this year's National Consortium of Breast Centers conference in Las Vegas to showcase its software advancements that are powering 's progressive breast centers.
-
Masimo Announces Changes to Governance Structure and Practices
3/23/2023
Masimo Corporation announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders.
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
3/23/2023
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
-
MIMEDX Announces Chief Financial Officer Transition
3/23/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities.
-
Exscientia Business and Financial Update for the Full Year 2022
3/23/2023
Exscientia plc. Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.